The Waldenstrom macroglobulinemia market is witnessing steady growth driven by advances in targeted therapies, particularly BTK inhibitors like IMBRUVICA and BRUKINSA. Rising awareness, improved ...

Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in ...

Sotatercept-csrk was first approved in 2024 to treat pulmonary arterial hypertension (PAH) in adults based on results seen in the phase 3 STELLAR trial.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

As policymakers consider the future of American healthcare, it is imperative to recognize the potential dangers of adopting ...

KALA Bio completes enrollment in CHASE trial, advancing KPI-012 for treating persistent corneal epithelial defects. Topline ...

Allison Gardner MP dedicated her support for the Rare Cancers Bill to her mother, who died of pancreatic cancer.

XOMA Royalty’s acquisition of Turnstone Biologics highlights how royalty deals can revive biopharma companies and drive ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical ...

Hospitals could be on the hook for significantly higher outpatient drug prices. Because of the cuts to Medicaid, hospitals in the 340B program will see fewer Medicaid patients and may risk losing ...